AR048945A1 - Pronostico para leucemia mieloide cronica - Google Patents

Pronostico para leucemia mieloide cronica

Info

Publication number
AR048945A1
AR048945A1 ARP050101846A ARP050101846A AR048945A1 AR 048945 A1 AR048945 A1 AR 048945A1 AR P050101846 A ARP050101846 A AR P050101846A AR P050101846 A ARP050101846 A AR P050101846A AR 048945 A1 AR048945 A1 AR 048945A1
Authority
AR
Argentina
Prior art keywords
patient
treatment
methods
ftis
prognosis
Prior art date
Application number
ARP050101846A
Other languages
English (en)
Original Assignee
Veridex Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Veridex Llc filed Critical Veridex Llc
Publication of AR048945A1 publication Critical patent/AR048945A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/483—Physical analysis of biological material
    • G01N33/487—Physical analysis of biological material of liquid biological material
    • G01N33/49—Blood
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Ecology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los métodos para el tratamiento de pacientes con cáncer y preferentemente con una enfermedad hematologica incluyen el análisis de los perfiles de expresion génica y/o marcadores moleculares de un paciente para determinar el estado y/o pronostico del paciente. Se proporcionan métodos para analizar si un paciente no recurrente o no refractario tiene probabilidad de responder al tratamiento con inhibidores de la farnesil-transferasa (FTIs, ôfarnesyl transferase inhibitorsö) y, opcionalmente, con otros agentes terapéuticos. Los métodos son también utiles para el monitoreo de la terapia del paciente y para la seleccion de un procedimiento de terapia. Los genes modulados como respuesta al tratamiento con los FTIs son proporcionados y utilizados para la formulacion de los perfiles. Reivindicacion 1: Un método de determinacion del pronostico para un individuo con neoplasia hematologica que comprende el análisis de la expresion de un grupo de genes que corresponden a la SEC ID NO. 1-167.
ARP050101846A 2004-05-06 2005-05-06 Pronostico para leucemia mieloide cronica AR048945A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56863504P 2004-05-06 2004-05-06

Publications (1)

Publication Number Publication Date
AR048945A1 true AR048945A1 (es) 2006-06-14

Family

ID=35262133

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050101846A AR048945A1 (es) 2004-05-06 2005-05-06 Pronostico para leucemia mieloide cronica

Country Status (9)

Country Link
EP (1) EP1612281A3 (es)
JP (1) JP2005333987A (es)
KR (1) KR20060045950A (es)
CN (1) CN1704478A (es)
AR (1) AR048945A1 (es)
AU (1) AU2005201935B2 (es)
BR (1) BRPI0503418A (es)
CA (1) CA2504403A1 (es)
MX (1) MXPA05004971A (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101156067A (zh) * 2005-02-16 2008-04-02 惠氏公司 用于白血病诊断、预后和治疗选择的方法和系统
US20080090242A1 (en) * 2006-09-29 2008-04-17 Schering Corporation Panel of biomarkers for prediction of fti efficacy
JP2012513197A (ja) * 2008-12-23 2012-06-14 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 無再発生存を予測するためのメチル化バイオマーカー
KR102136041B1 (ko) * 2010-04-29 2020-07-20 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 게놈 모델에 대한 데이터 통합을 이용하는 경로 인지 알고리즘 （ｐａｒａｄｉｇｍ）
RU2478206C1 (ru) * 2012-02-06 2013-03-27 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт медицинских проблем Севера" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИМПС" СО РАМН) Способ прогнозирования рецидивов у больных острым лейкозом
EP3327141B1 (en) * 2013-04-19 2020-01-29 Epiontis GmbH Method for identifying the quantitative cellular composition in a biological sample
RU2550944C2 (ru) * 2013-08-08 2015-05-20 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт медицинских проблем Севера" Сибирского отделения Российской академии медицинских наук (ФГБУ "НИИМПС" СО РАМН) Способ прогнозирования развития терминальной стадии у больных хроническим миелолейкозом
WO2015144841A1 (en) * 2014-03-26 2015-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) New biomarker for outcome in aml patients
CA3118081A1 (en) * 2018-10-30 2020-05-07 Macrogenics, Inc. Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies
RU2738563C1 (ru) * 2020-09-18 2020-12-14 Ен Джун Чой Способ прогноза малигнизации и ранней диагностики злокачественных опухолей
CN112250750B (zh) * 2020-10-21 2022-08-30 青岛肿瘤研究院 与含酪氨酸磷酸化修饰肽具有亲和力的变体sh2结构域

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1470247A2 (en) * 2001-11-05 2004-10-27 Deutsches Krebsforschungszentrum Novel genetic markers for leukemias
US20050003422A1 (en) * 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
AU2004202980B2 (en) * 2003-07-01 2009-05-07 Veridex, Llc Methods for assessing and treating leukemia

Also Published As

Publication number Publication date
CN1704478A (zh) 2005-12-07
MXPA05004971A (es) 2005-11-23
AU2005201935A1 (en) 2005-11-24
KR20060045950A (ko) 2006-05-17
EP1612281A3 (en) 2007-02-21
EP1612281A2 (en) 2006-01-04
BRPI0503418A (pt) 2006-04-11
CA2504403A1 (en) 2005-11-06
JP2005333987A (ja) 2005-12-08
AU2005201935B2 (en) 2012-04-26

Similar Documents

Publication Publication Date Title
AR048945A1 (es) Pronostico para leucemia mieloide cronica
AR049564A1 (es) Metodos para la evaluacion y tratamiento del cancer
Yoshimoto et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement
Widemann Current status of sporadic and neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors
MX2007007401A (es) Metodos para evaluar a pacientes con leucemia mieloide aguda.
Hermanek et al. Prognostic factors in cancer
Fong et al. Comparison of melanoma guidelines in the USA, Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review
Jun et al. Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma
WO2012006589A3 (en) Methods and compositions for identification, assessment and treatment of cancers associated with hedgehog signaling
DE60222590D1 (de) Methoden zur feststellung von akute myeloischen leukämie
MX2009012722A (es) Variantes geneticas sobre chr 5p12 y 10q26 como marcadores para el uso en la evaluacion del riesgo, diagnostico, pronostico y tratamiento del cancer de mama.
CR9315A (es) Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia
MXPA05005923A (es) Metodos para la identificacion, valoracion y tratamiento de pacientes con terapia para la inhibicion de la proteasoma.
ATE498693T1 (de) Marker zur prognose der reaktion auf therapie bzw. der überlebensrate von brustkrebspatienten
Tarullo et al. Postpartum breast cancer progression is driven by semaphorin 7a-mediated invasion and survival
Xu et al. Overexpression of DDR2 contributes to cell invasion and migration in head and neck squamous cell carcinoma
NI200700126A (es) Metodos y sistemas para el pronostico y tratamiento de tumores solidos
DE69717664D1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
BRPI0607507A2 (pt) método in vitro para a identificação de compostos para tratamento do cáncer
AR032917A1 (es) Metodo para determinar la expresion de genes de dihidropirimidina deshidrogenasa
Singh et al. Induction of CaSR expression circumvents the molecular features of malignant CaSR null colon cancer cells
BR112021016595A2 (pt) Método de diagnóstico ou prognóstico de câncer, métodos para diagnosticar câncer ou para triagem de câncer, para monitorar um indivíduo, para monitorar o tratamento de câncer, para avaliar a resposta de um indivíduo a um tratamento de câncer e para tratar um indivíduo com câncer detectado, kit e uso do kit
ATE545867T1 (de) I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom
Wuidar et al. Sex-based differences in the tumor microenvironment
Tuech et al. Sentinel node mapping in colon carcinoma: in-vivo versus ex-vivo approach

Legal Events

Date Code Title Description
FA Abandonment or withdrawal